Glaxo Wellcome Relenza

Influenza A and B therapy gains additional indication April 27 for treatment of pediatric patients seven and older who have been symptomatic for no more than two days. Zanamivir was previously approved for treatment of patients over 12. The pediatric dose is the same as for adults, 10 mg twice daily